| 1 |
|
Cancer Research UK's CRT: A Bridge Between Big Pharma And Academia
|
Stovall, S.
|
Channing, Weinberg & Co
|
2013
|
|
|
|
| 2 |
|
Can Isis Remain A Platform Company?
|
Goodman, M.
|
Channing, Weinberg & Co
|
2013
|
|
|
|
| 3 |
|
Can MDCO Make Alnylam's PCSK9 Candidate Work In The Hospital? Lagging the antibodies, The Medicine's Co.'s novel approach to the PCSK9 race brings certain strenghts, not the least being a fundamentally different mechanism. Moreover, being last may not be least in a field that's changing as rapidly as lipidology
|
Goodman, M.
|
Channing, Weinberg & Co
|
2013
|
|
|
|
| 4 |
|
Can Merck Serono Bounce Back?
|
Morrison, C.
|
Channing, Weinberg & Co
|
2013
|
|
|
|
| 5 |
|
Can MicroPort Master Orthopedics?
|
Salemi, T.
|
Channing, Weinberg & Co
|
2014
|
|
|
|
| 6 |
|
Can Simpirica Simplify Spine Stabilization?
|
Salemi, T.
|
Channing, Weinberg & Co
|
2012
|
|
|
|
| 7 |
|
Capital allocation in the age of shareholder activism
|
Greene, Jeffrey; Licking, Ellen
|
Channing, Weinberg & Co
|
2015
|
|
|
|
| 8 |
|
Capturing Value From Connected Health
|
Rosenberg, Rena; VanLare, Jordan; Reinholt, Bryan; Rao, Satya; Dertouzos, Joe
|
Channing, Weinberg & Co
|
2015
|
|
|
|
| 9 |
|
CardiNor Leads The Charge As Norway Gets Behind Life Sciences
|
Yeo, Ashley
|
Channing, Weinberg & Co
|
2016
|
|
|
|
| 10 |
|
Cardionovum: As DEBs Heat Up, Who Needs The US Market?: Michael Orlowski proved with his first company that you can build a successful interventional cardiology company steering clear of the US. Can he do it again?
|
Cassak, D.
|
Channing, Weinberg & Co
|
2012
|
|
|
|
| 11 |
|
Cartilage Regeneration: Solving The Unsolvable?
|
O Reilly, Sharon
|
Channing, Weinberg & Co
|
2015
|
|
|
|
| 12 |
|
Challenges For Bioresorbable Stents In Peripheral Arterial Disease
|
Ratner, M.
|
Channing, Weinberg & Co
|
2014
|
|
|
|
| 13 |
|
Changing Form, But Not Function: Smith & Nephew Expands NPWT Market
|
Stuart, M.
|
Channing, Weinberg & Co
|
2012
|
|
|
|
| 14 |
|
Changing Mind-Set Spurring Robotics In Ortho Surgery
|
Yeo, Ashley
|
Channing, Weinberg & Co
|
2015
|
|
|
|
| 15 |
|
Channel Preference Versus Promotional Reality: The Core Challenge Of Multichannel Marketing
|
Rickwood, Sarah; Dabbs, Gareth; Smith, Alexandra; Wooden, Christopher
|
Channing, Weinberg & Co
|
2016
|
|
|
|
| 16 |
|
CircuLite: Treating Heart Failure's Lost Patients
|
Cassak, D.
|
Channing, Weinberg & Co.
|
2013
|
|
|
|
| 17 |
|
Cleveland Clinic Innovations: Creating A Global Innovation Engine
|
Cassak, D.
|
Channing, Weinberg & Co
|
2012
|
|
|
|
| 18 |
|
Clinical Trial Success Rates Still Dismal, But Certain Sectors Outperform Informa Pharma Intelligence's Biomedtracker teamed up with BIO and Amplion to provide an update on clinical development success rates from 2006 to 2015, including a new analysis on trials incorporating patient selection biomarkers
|
Micklus, Amanda
|
Channing, Weinberg & Co
|
2016
|
|
|
|
| 19 |
|
CNS drug development: the landscape
|
Gamble, Tim
|
Channing, Weinberg & Co
|
2014
|
|
|
|
| 20 |
|
Commercialization Alternatives In The New Medtech World
|
Posner, S.A.; Speers, M.S.
|
Channing, Weinberg & Co
|
2012
|
|
|
|